Lee Henderson | Chief Executive Officer And Founder
Vybion

Lee Henderson, Chief Executive Officer And Founder, Vybion

Lee Henderson, Ph.D. has managed the contract development of over 10 biologic drugs for a wide range of indications, has an extensive background in viral diseases and was an active member of the Hemorrhagic Fever Virus Consortium which developed the first FDA approved diagnostic assays for Lassa Fever and Ebola viruses. He collaborated with a group at Caltech and subsequently developed INT41, a first in class disease modifying Intrabody Gene Therapy for Huntington’s Disease currently in preclinical development. 

Lee has helped launch and fund several startups companies including GeneWeave Biosciences and served on Advisory boards at Cornell University and the Rochester Institute of Technology. He was a faculty member at Tulane Medical School and Director of Molecular Virology for the Guthrie Research Institute. Lee received a PhD from the University of South Carolina in Biochemistry in 1981 and was a postdoctoral fellow for the Cancer Research institute at University of Texas Health Science Center in Dallas. 

Appearances:



World Orphan Drug Congress USA 2019 - Day 2 @ 12:05

Pitch 19: INT41, an Intrabody Gene Therapy for Treating Huntington’s Disease

last published: 20/Mar/19 21:45 GMT

back to speakers